BTK inhibitor tolebrutinib in the treatment of multiple sclerosis (MS) shows "promising" results

Multiple sclerosis (MS) is a kind of demyelinating neuropathy.
The insulating material (myelin sheath) on the surface of nerve cells in the brain or spinal cord of the patient is damaged, and the signal transduction of the nervous system is impaired, leading to a series of possible The symptoms that occur affect the patient's activity, mind, and even mental state
.

These symptoms may include diplopia, impaired vision on one side, muscle weakness, hypoesthesia, or coordination problems

The three important characteristics of multiple sclerosis include the appearance of central nervous system lesions, inflammation, and destruction of myelin sheath
.

The disease most commonly affects the optic nerve, brain stem, basal nucleus, spinal cord, and white matter around the lateral ventricle

Recently, the French pharmaceutical company Sanofi announced new long-term data on its research oral Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib.
The results show that tolebrutinib is shown in patients with relapsed and refractory multiple sclerosis (MS) Develop "promising" safety and effectiveness
.

Recently, the French pharmaceutical company Sanofi announced new long-term data on its research oral Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib.
The results show that tolebrutinib is shown in patients with relapsed and refractory multiple sclerosis (MS) "Promising" safety and effectiveness
.

Recently, the French pharmaceutical company Sanofi announced new long-term data on its research oral Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib.

Figure 1.
Estimated dose-response curve after applying the two-step multiple comparison procedure and modeling

Figure 1.
Estimated dose-response curve after applying two-step multiple comparison procedure and modeling Figure 1.
Estimated dose-response curve after applying two-step multiple comparison procedure and modeling

The results of the Phase IIb Long-Term Extended Study (LTS) showed that after 48 weeks of treatment, the BTK inhibitor tolebrutinib reduced the activity of multiple sclerosis (MS) disease
.

According to Sanofi, according to "public information," this data makes tolebrutinib the only BTK inhibitor under development for MS, which has been shown to directly regulate microglia
.

Erik Wallström, head of Sanofi neurology development, said: “Understanding the ability of brain penetration therapy to slow down the accumulation of disability may bring new hope to patients with refractory MS
.

For nearly two decades, Sanofi has been unswervingly Work hard to expedite the provision of treatment options for these patients"

Currently, tolebrutinib is being evaluated in phase III clinical trials for the treatment of MS, non-recurrent secondary progressive MS (nrSPMS) and primary progressive MS (PPMS)

 

Original source:

Original source:

http:// href="http://" target="_blank" rel="noopener">http:// http:// in this message